{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:28:34Z","timestamp":1769632114766,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takeda Pharmaceuticals"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5600-x","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:03:39Z","timestamp":1559034219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction\/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7803-0814","authenticated-orcid":false,"given":"Hans","family":"Salwender","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Duerig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Benner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor W.","family":"Blau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc Steffen","family":"Raab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Huhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindaugas","family":"Andrulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Seidel-Glaetzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Walter","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Hensel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Fronhoffs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Martens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timon","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Wattad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ullrich","family":"Graeven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Munder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Fenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Haenel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"5600_CR1","unstructured":"DGHO - German Society for Hematology and Oncology: Onkopedia guidelines multiple myeloma 2018 (09.02.2019)."},{"issue":"11","key":"5600_CR2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046\u201360.","journal-title":"N Engl J Med"},{"issue":"23","key":"5600_CR3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V126.23.391.391","volume":"126","author":"M Attal","year":"2015","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Facon T, Caillot D, Escoffre M, Arnulf B, Marco M, Belhadj K, Garderet L, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe francophone Du Myelome (IFM\/DFCI 2009 trial). Blood. 2015;126(23):391.","journal-title":"Blood"},{"issue":"22","key":"5600_CR4","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V128.22.991.991","volume":"128","author":"M Cavo","year":"2016","unstructured":"Cavo M, Petrucci MT, Di Raimondo F, Zamagni E, Gamberi B, Crippa C, Marzocchi G, Grasso M, Ballanti S, Vincelli DI, et al. Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European myeloma network (EMN02\/HO95 MM trial). Blood. 2016;128(22):991.","journal-title":"Blood"},{"issue":"3","key":"5600_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2014-03-561985","volume":"124","author":"F van Rhee","year":"2014","unstructured":"van Rhee F, Giralt S, Barlogie B. The future of autologous stem cell transplantation in myeloma. Blood. 2014;124(3):328\u201333.","journal-title":"Blood"},{"issue":"5","key":"5600_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679\u201386.","journal-title":"Blood"},{"issue":"25","key":"5600_CR7","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"M Roussel","year":"2014","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, Fruchart C, Stoppa AM, Gentil C, Wuilleme S, Huynh A, Hebraud B, Corre J, Chretien ML, Facon T, Avet-Loiseau H, Attal M. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe francophone du My\u00e9lome. J Clin Oncol. 2014;32(25):2712\u20137.","journal-title":"J Clin Oncol"},{"issue":"19","key":"5600_CR8","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375\u201382.","journal-title":"Blood"},{"issue":"8","key":"5600_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1634\/theoncologist.2014-0042","volume":"19","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Sonneveld P, Davies F, Blade J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, Dimopoulos M, Einsele H, Facon T, Goldschmidt H, Moreau P, Nahi H, Plesner T, San-Miguel J, Hajek R, Sondergeld P, Palumbo A. European perspective on multiple myeloma treatment strategies in 2014. Oncologist. 2014;19(8):829\u201344.","journal-title":"Oncologist"},{"key":"5600_CR10","volume-title":"Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe francophone Du Myelome. Abstract ASH 2015, 57th annual meeting","author":"M Attal","year":"2015","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Facon T, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Mathiot C, Avet-Loiseau H, Munshi NC, Richardson PG, Anderson KC, Harousseau JL, Moreau P. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe francophone Du Myelome. Abstract ASH 2015, 57th annual meeting; 2015."},{"issue":"10068","key":"5600_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519\u201327.","journal-title":"Lancet"},{"issue":"5","key":"5600_CR12","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1053\/j.seminoncol.2013.07.008","volume":"40","author":"H Liu","year":"2013","unstructured":"Liu H, McCarthy P. New developments in post-transplant maintenance treatment of multiple myeloma. Semin Oncol. 2013;40(5):602\u20139.","journal-title":"Semin Oncol"},{"issue":"29","key":"5600_CR13","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279\u201389.","journal-title":"J Clin Oncol"},{"issue":"19","key":"5600_CR14","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa A, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans M-C, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau J-L. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782\u201391.","journal-title":"N Engl J Med"},{"issue":"19","key":"5600_CR15","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770\u201381.","journal-title":"N Engl J Med"},{"issue":"7","key":"5600_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Rollig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"5600_CR17","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjh.14787","volume":"178","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P. Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178(6):896\u2013905.","journal-title":"Br J Haematol"},{"key":"5600_CR18","unstructured":"Southwest Oncology Group: S1211, bortezomib, dexamethasone, and lenalidomide with or without elotuzumab in treating patients with newly diagnosed high-risk multiple myeloma. \n                    www.clinicaltrials.gov\n                    \n                   NCT01668719 (05.08.2014)."},{"issue":"15_suppl","key":"5600_CR19","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2017.35.15_suppl.8002","volume":"35","author":"J Laubach","year":"2017","unstructured":"Laubach J, Nooka AK, Cole C, O'Donnell E, Vij R, Usmani SZ, Orloff GJ, Richter JR, Redd R, DiPietro H, et al. An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma. J Clin Oncol. 2017;35(15_suppl):8002.","journal-title":"J Clin Oncol"},{"issue":"12","key":"5600_CR20","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","volume":"2","author":"PG Richardson","year":"2015","unstructured":"Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematology. 2015;2(12):e516\u201327.","journal-title":"Lancet Haematology"},{"issue":"16","key":"5600_CR21","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","volume":"30","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DE, Singhal AK, Anderson KC. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2012;30(16):1960\u20135.","journal-title":"J Clin Oncol"},{"issue":"3","key":"5600_CR22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","volume":"120","author":"JA Zonder","year":"2012","unstructured":"Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DE, Singhal AK. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552\u20139.","journal-title":"Blood"},{"issue":"16","key":"5600_CR23","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","volume":"30","author":"S Lonial","year":"2012","unstructured":"Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953\u20139.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"5600_CR24","doi-asserted-by":"crossref","first-page":"8542","DOI":"10.1200\/jco.2013.31.15_suppl.8542","volume":"31","author":"S Lonial","year":"2013","unstructured":"Lonial S, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, Bleickardt E, Reece DE, Benboubker L, et al. Phase (Ph) I\/II study of elotuzumab (Elo) plus lenalidomide\/dexamethasone (Len\/dex) in relapsed\/refractory multiple myeloma (RR MM): updated Ph II results and Ph I\/II long-term safety. J Clin Oncol. 2013;31(15_suppl):8542.","journal-title":"J Clin Oncol"},{"issue":"9","key":"5600_CR25","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467\u201373.","journal-title":"Leukemia"},{"issue":"5","key":"5600_CR26","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation . Myeloma Subcommittee of the EBMT European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115\u201323.","journal-title":"Br J Haematol"},{"issue":"5","key":"5600_CR27","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"The international Myeloma Working Group","year":"2003","unstructured":"The international Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol. 2003;121(5):749\u201357.","journal-title":"Br J Haematol"},{"issue":"15","key":"5600_CR28","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1002\/sim.2517","volume":"25","author":"FM Barthel","year":"2006","unstructured":"Barthel FM, Babiker A, Royston P, Parmar MK. Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over. Stat Med. 2006;25(15):2521\u201342.","journal-title":"Stat Med"},{"issue":"18","key":"5600_CR29","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1002\/sim.2151","volume":"24","author":"JM Lachin","year":"2005","unstructured":"Lachin JM. A review of methods for futility stopping based on conditional power. Stat Med. 2005;24(18):2747\u201364.","journal-title":"Stat Med"},{"issue":"2","key":"5600_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0197-2456(94)00030-7","volume":"16","author":"PY Liu","year":"1995","unstructured":"Liu PY, Dahlberg S. Design and analysis of multiarm clinical trials with survival endpoints. Control Clin Trials. 1995;16(2):119\u201330.","journal-title":"Control Clin Trials"},{"issue":"16","key":"5600_CR31","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","volume":"16","author":"F Gay","year":"2015","unstructured":"Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petro D, Evangelista A, Spada S, Pescosta N, Omede P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617\u201329.","journal-title":"Lancet Oncol"},{"issue":"10","key":"5600_CR32","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omede P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895\u2013905.","journal-title":"N Engl J Med"},{"key":"5600_CR33","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V128.22.991.991","volume":"128","author":"M Cavo","year":"2016","unstructured":"Cavo M. Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European myeloma network (EMN02\/HO95 MM trial). Blood. 2016;128:991.","journal-title":"Blood"},{"key":"5600_CR34","first-page":"435","volume":"130","author":"A-L Herv\u00e9","year":"2017","unstructured":"Herv\u00e9 A-L, Valerie L-C, Jill C, Philippe M, Michel A, Nikhil M. Minimal residual disease in multiple myeloma: final analysis of the IFM2009 trial. Blood. 2017;130:435.","journal-title":"Blood"},{"issue":"25","key":"5600_CR35","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, Facon T, Benboubker L, Escoffre-Barbe M, Stoppa AM, et al. Prospective evaluation of magnetic resonance imaging and [(18)F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(25):2911\u20138.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5600-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5600-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5600-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T23:08:51Z","timestamp":1590534531000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5600-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5600"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5600-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"assertion":[{"value":"7 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Documented approval from the appropriate ethics committees\/institutional review boards (IRB) of the Medical Faculty of the Heidelberg University (main IRB) and all participating study sites has been obtained prior to study start and a data safety monitoring board (DSMB) has been installed to monitor the trial. Written informed consent from each patient is obtained before any study-specific procedures are performed. A full list of involved\/ local ethicscommittees is provided in the accepting assessment documents in a separate file.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"At this time (04\/05\/2018), only abstracts regarding the HD6 trial have been published (e.g. ASH Abstract 2016:Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial; P Wuchter et al; Blood 2016 128:3373). The trial protocol has not been openly published in a peer reviewed paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author-specific disclosures: HS: Celgene: Honoraria, Travel grants; Bristol Myers Squibb: Honoraria and Research Funding; Amgen: Honoraria, Travel grants; Janssen: Honoraria and Research Funding; Novartis: Honoraria and Research Funding; Takeda: Honoraria. KW: Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees and Research Funding; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees and Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees and Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees and Research Funding Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees and Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees and Research Funding; Sanofi: Research Funding. JD: Celgene: Honoraria, Research Funding and Speakers Bureau; Janssen: Honoraria and Speakers Bureau . MSR: Celgene: Honoraria, Research Funding, Speakers Bureau; Bristol Myers Squibb: Consultancy and Speakers Bureau; Amgen: Honoraria, Research Funding, Speakers Bureau; Novartis: Consultancy and Research Funding; Morphosys: Research Funding. JH: Celgene: Consultancy, Honoraria and Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria; Amgen: Consultancy, Honoraria and Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria and Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria and Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria; Sanofi: Research Funding. DH: Celgene: Consultancy, Research Funding; MM: Janssen: Consultancy; Bristol Myers Squibb: Consultancy; Takeda: Consultancy; Amgen: Consultancy Celgene: Consultancy. RF: Celgene: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria. MHa: Roche: Honoraria; Novartis: Honoraria. HG: Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding and Speakers Bureau; Chugai: Consultancy, Honoraria and Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding and Speakers Bureau Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding and Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding and Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding and Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding and Speakers Bureau. All other authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"504"}}